Therapeutic results in patients with relapsed diffuse large B cell non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

Hematological Oncology

Volumn 24, Issue 2, 2006, Pages 73-77

  Ferrara, Felicetto ^a,b   Viola, Assunta ^a   Copia, Carolina ^a   Schiavone, Ettore Mariano ^a   Celentano, Maria ^a   Pollio, Filiberto ^a   D'Amico, Maria Rosaria ^a   Palmieri, Salvatore ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Autologous transplantation; Non Hodgkin lymphoma; Relapse

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE DERIVATIVE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33745793604     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.773     Document Type: Article

References (40)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
2. Couderc B, Dujols JP, Mokhtari F, Norkowski JL, Slawinski JC, Schlaifer D. The management of adult aggressive non-Hodgkin's lymphomas. Crit Rev Oncol Hematol 2000; 35: 33-48.
3. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004; 5: 341-353.
4. Wooldridge JE, Link BK. Post-treatment surveillance of patients with lymphoma treated with curative intent. Semin Oncol 2003; 30: 375-381.
5. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal of Clinical Oncology 1992; 10: 210-218.
6. Salles G, Shipp MA, Coiffier B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Seminars in Hematology 1994; 31: 46-69.
7. Lin TS, Copelan EA. Autologous Stem Cell Transplantation for Non-Hodgkin's Lymphoma. Curr Hemat Rep 2003; 2: 310-315.
8. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
9. Vose JM, Zhang M-J, Rowlings PA, et al. Autologous Transplantation for Diffuse Aggressive Non-Hodgkin's Lymphoma in Patients Never Achieving Remission: a Report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
10. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003; 32: 673-679.
11. Prince HM, Imrie K, Crump M, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880-889.
12. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
13. Zinzani PL, Tani M, Molinari AL, et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816-821.
14. Pocali B, Desimone M, Annunziata M, et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45: 1605-1609.
15. Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9: 423-431.
16. Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004; 72: 10-17.
17. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
18. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens- a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48-55.
19. Shipp M, Harrington D, Anderson J, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1251.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Marcus R. Current treatment options in aggressive lymphoma. Leuk Lymphoma 2003; 44(Suppl. 4): S15-S27.
23. Coiffier B. Treatment of Diffuse Large B-cell Lymphoma. Curr Hematol Rep 2005; 4: 7-14.
24. Bertz H, Zeiser R, Lange W, Fetscher S, Waller CF, Finke J. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol 2004; 15: 1419-1424.
25. Paltiel O, Rubinstein C, Or R, et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003; 31: 565-569.
26. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Brit J Haematol 2005; 130: 363-372.
27. Josting A, Sieniawski M, Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16: 1359-1365.
28. Ahmed T, Rashid K, Waheed F, et al. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma 2005; 46: 405-414.
29. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996.
30. Sugrue MW, Williams K, Pollock BH, et al. Characterization and outcome of 'hard to mobilize' lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymph 2000; 39: 509-519.
31. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymph 2003; 44: 815-820.
32. Waheed F, Kancherla R, Seiter K, et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma 2004; 45: 2253-2259.
33. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004; 10: 116-127.
34. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561-4566.
35. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.
36. Davis TA, Hsu FJ, Caspar CB, et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant 2001; 7: 517-522.
37. Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004; 31: 22-26.
38. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
39. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
40. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-3162.